15 Einträge gefunden

1. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer:AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

   1. Pfisterer, Jacobus
   2. Joly, Florence
   3. Kristensen, Gunnar
   4. Rau, Joern
   5. Mahner, Sven
   6. Pautier, Patricia
   7. El-Balat, Ahmed

   2023 - Forschungsinformationssystem des UKE
2. The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium

   1. Obermayr, Eva
   2. Reiner, Angelika
   3. Brandt, Burkhard
   4. Braicu, Elena Ioana
   5. Reinthaller, Alexander
   6. Loverix, Liselore
   7. Concin, Nicole

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium

   1. Obermayr, Eva
   2. Braicu, Elena Ioana
   3. Polterauer, Stephan
   4. Loverix, Liselore
   5. Concin, Nicole
   6. Woelber, Linn
   7. Mahner, Sven

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Prognostic role of thrombocytosis in recurrent ovarian cancer:a pooled analysis of the AGO Study Group

   1. Canzler, Ulrich
   2. Lück, Hans-Joachim
   3. Neuser, Petra
   4. Sehouli, Jalid
   5. Burges, Alexander
   6. Harter, Philipp
   7. Schmalfeldt, Barbara

   2020 - Forschungsinformationssystem des UKE
5. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study

   1. Mahner, Sven
   2. Jueckstock, Julia
   3. Hilpert, Felix
   4. Neuser, Petra
   5. Harter, Philipp
   6. de Gregorio, Nikolaus
   7. Hasenburg, Annette

   2015 - Forschungsinformationssystem des UKE
6. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study

   1. Fotopoulou, Christina
   2. Sehouli, Jalid
   3. Ewald-Riegler, Nina
   4. de Gregorio, Nikolaus
   5. Reuss, Alexander
   6. Richter, Rolf
   7. Mahner, Sven

   2015 - Forschungsinformationssystem des UKE
7. Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

   1. Aust, Stefanie
   2. Auer, Katharina
   3. Bachmayr-Heyda, Anna
   4. Denkert, Carsten
   5. Sehouli, Jalid
   6. Braicu, Ioana
   7. Mahner, Sven

   2014 - Forschungsinformationssystem des UKE - frei zugänglich
8. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium

   1. Melmer, Andreas
   2. Fineder, Linda
   3. Lamina, Claudia
   4. Kollerits, Barbara
   5. Dieplinger, Benjamin
   6. Braicu, Ioana
   7. Sehouli, Jalid

   2013 - Forschungsinformationssystem des UKE
9. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium

   1. Obermayr, Eva
   2. Castillo-Tong, Dan Cacsire
   3. Pils, Dietmar
   4. Speiser, Paul
   5. Braicu, Ioana
   6. Van Gorp, Toon
   7. Mahner, Sven

   2013 - Forschungsinformationssystem des UKE
10. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium

    1. Bachmayr-Heyda, Anna
    2. Aust, Stefanie
    3. Heinze, Georg
    4. Polterauer, Stephan
    5. Grimm, Christoph
    6. Braicu, Elena Ioana
    7. Sehouli, Jalid

    2013 - Forschungsinformationssystem des UKE - frei zugänglich
11. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

    1. Sehouli, Jalid
    2. Stengel, Dirk
    3. Harter, Philipp
    4. Kurzeder, Christian
    5. Belau, Antje
    6. Bogenrieder, Thomas
    7. Markmann, Susanne

    2011 - Forschungsinformationssystem des UKE
12. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.

    1. Sehouli, Jalid
    2. Pietzner, K
    3. Harter, P
    4. Münstedt, K
    5. Mahner, Sven
    6. Hasenburg, A
    7. Camara, O

    2010 - Forschungsinformationssystem des UKE
13. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.

    1. Sehouli, Jalid
    2. Camara, Oumar
    3. Mahner, Sven
    4. Bauknecht, Thomas
    5. Lichtenegger, Werner
    6. Runnebaum, Ingo
    7. Look, Katherine

    2010 - Forschungsinformationssystem des UKE
14. Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction.

    1. Mahner, Sven
    2. Wölber, Linn
    3. Jung, Sabine
    4. Zu Eulenburg, Christine Gräfin
    5. Henningsen, Maike
    6. Schwarz, Joerg
    7. Sehouli, Jalid

    2009 - Forschungsinformationssystem des UKE
15. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

    1. Sehouli, Jalid
    2. Camara, O
    3. Schmidt, M
    4. Mahner, Sven
    5. Seipelt, G
    6. Otremba, B
    7. Schmalfeldt, B

    2009 - Forschungsinformationssystem des UKE